INSMED ANNOUNCES RESULTS OF IPLEX™ PHASE II
TRIAL IN MYOTONIC MUSCULAR DYSTROPHY
Insmed to Evaluate Potential Initiation of Phase II Trial for IPLEX™
in MMD Patients with Severe Insulin Resistance
RICHMOND, VA., June 25, 2009 - Insmed Inc. (NASDAQ CM: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX™ (mecasermin rinfabate) in patients with myotonic muscular dystrophy (“MMD”). The randomized, double-blind, place…
Continue
Posted on June 25, 2009 at 6:24pm — 1 Comment